Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R55" target="_blank" >RIV/61988987:17110/17:A1801R55 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/17:10362456 RIV/00843989:_____/17:E0106326 RIV/00064165:_____/17:10362456
Result on the web
<a href="http://dx.doi.org/10.1111/bjh.14549" target="_blank" >http://dx.doi.org/10.1111/bjh.14549</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.14549" target="_blank" >10.1111/bjh.14549</a>
Alternative languages
Result language
angličtina
Original language name
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Original language description
A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM). This post hoc analysis examined outcomes from ASPIRE in patients categorised by age. In the carfilzomib group, 103/396 patients were 70years old, and in the control group, 115/396 patients were 70years old. Median PFS for patients <70years old was 286months for the carfilzomib group versus 176months for the control group [hazard ratio (HR), 0701]. Median PFS for patients 70years old was 238months for the carfilzomib group versus 160months for the control group (HR, 0753). For patients <70years the overall response rate (ORR) was 860% (carfilzomib group) and 669% (control group); for patients 70years old the ORR was 903% (carfilzomib group) and 661% (control group). Within the carfilzomib group, grade 3 cardiovascular adverse events occurred more frequently among patients 70years old compared with patients <70years old. Carfilzomib-lenalidomide-dexamethasone has a favourable benefit-risk profile for patients with RMM, including elderly patients 70years old. Trial Registration: clinicaltrials.gov identifier: NCT01080391.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BRITISH JOURNAL OF HAEMATOLOGY
ISSN
0007-1048
e-ISSN
1365-2141
Volume of the periodical
177
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
404-413
UT code for WoS article
000399957200010
EID of the result in the Scopus database
2-s2.0-85013483834